The US Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application for GSK‘s dostarlimab-gxly (Jemperli) to treat previously untreated stage 2 and 3 mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced rectal cancer, establishing a target action date of February 2027.
Regulatory Momentum and Clinical Trial Architecture
The FDA accepted the application under the Prescription Drug User Fee Act, setting a PDUFA action date for February 2027, according to updates from Pharmacy Times. Furthermore, the submission qualifies for expedited review through the National Priority Voucher program and was accepted under Project Orbis. This multi-agency initiative managed by the FDA’s Oncology Center of Excellence permits concurrent review of oncology assets across participating international regulatory bodies.
Here is the math behind the therapeutic candidate: dostarlimab is a programmed cell death receptor-1 (PD-1) blocking antibody designed for a specific patient demographic. Approximately 5% to 10% of rectal cancers exhibit dMMR or MSI-H biology. These tumors feature impaired mechanisms for repairing DNA replication errors, which leads to a higher accumulation of mutations. That molecular profile enhances tumor recognition by the patient’s immune system, increasing vulnerability to immune checkpoint inhibitors.
The Bottom Line
- Regulatory Timeline: The FDA assigned a PDUFA target action date of February 2027 under priority review.
- Clinical Foundation: The sBLA relies on interim data from the 154-patient, phase 2 AZUR-1 trial (NCT05723562) evaluating dostarlimab monotherapy.
- Market Position: If approved, dostarlimab could become the first immunotherapy indicated in this setting to eliminate or delay conventional chemotherapy, radiation, and surgery in this biomarker-defined population.
Unpacking the AZUR-1 Data and Organ-Preservation Strategy
The supplemental biologics license application relies directly on interim findings from the global, open-label, single-arm phase 2 AZUR-1 trial. The study enrolled 154 patients with previously untreated stage 2 or 3 dMMR/MSI-H locally advanced rectal cancer. Participants received intravenous dostarlimab monotherapy at a dose of 500 mg every 3 weeks for 9 cycles spanning 6 months, according to clinical disclosures reported by Targeted Oncology.
The trial met its primary objective by demonstrating a clinically meaningful proportion of participants achieving a sustained clinical complete response lasting at least 12 months, known as cCR12. A clinical complete response signifies that diagnostic evaluations reveal no detectable evidence of cancer following treatment. Detailed findings from the AZUR-1 cohort are slated for formal presentation at a scientific congress later in 2026.
| Trial Parameter | Clinical Metric |
|---|---|
| Compound & Ticker | Dostarlimab (Jemperli) — GSK |
| Indication | Stage 2/3 dMMR/MSI-H Locally Advanced Rectal Cancer |
| Study Design | Phase 2 AZUR-1 (Open-label, single-arm, n=154) |
| Regimen | 500 mg IV every 3 weeks for 9 cycles (6 months) |
| Primary Endpoint | Sustained clinical complete response at 12 months (cCR12) |
Commercial Implications and Therapeutic Shifts
Traditional care pathways for locally advanced rectal cancer demand multimodal interventions, combining chemotherapy, radiation, and radical surgery. While these protocols achieve disease control, they frequently impose long-term morbidity, including permanent alterations to bowel and urinary function, sexual health, fertility, and overall quality of life. But the balance sheet for patients changes significantly if nonoperative strategies prove durable.
“For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery,” noted Hesham Abdullah, senior vice president, global head oncology, R&D at GSK, in a previous statement regarding the trial. “These data demonstrate that some patients may be able to avoid those interventions while remaining free of detectable signs of cancer.”
These findings build heavily on foundational work executed at Memorial Sloan Kettering Cancer Center. An initial phase 2 study published in The New England Journal of Medicine observed that all 12 patients who completed 6 months of dostarlimab achieved a clinical complete response, bypassing chemoradiotherapy and surgery entirely without disease progression during follow-up. Subsequent longer-term evaluations cemented the viability of neoadjuvant PD-1 blockade as an organ-preserving modality.
Market Outlook for Oncology Assets
The drug previously secured fast track and breakthrough therapy designations from federal regulators for this exact indication.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
